Hypothesis\n\nNAD+ functions as a cellular budget sensor that translates senescent‑cell‑derived CD38 activity into a reversible down‑regulation of anabolic programs. When CD38+ immune cells hydrolyze NAD+ in adipose, liver and spleen, the resulting NAD+ dip reduces SIRT1‑ and SIRT3‑mediated deacetylation of PGC‑1α and FOXO transcription factors, shifting chromatin toward a repressed state that limits fatty‑acid oxidation and mitochondrial biogenesis. This metabolic downgrade is not passive decay; it is an active compensatory response that conserves NAD+ for essential processes like DNA repair while curbing costly biosynthetic pathways. The hypothesis predicts that lowering CD38 activity in tissue‑resident macrophages will raise local NAD+, restore SIRT‑driven deacetylation, and re‑activate anabolic circuits without altering the overall senescent‑cell load.\n\n### Mechanistic basis\n\n- Senescent cells secrete SASP factors that up‑regulate CD38 on infiltrating macrophages [1].\n- CD38’s NADase activity consumes NAD+ and its precursor NMN, creating a local nad+ sink [2].\n- Reduced NAD+ diminishes SIRT1 activity, leading to hyper‑acetylated PGC‑1α and suppressed mitochondrial gene expression [3].\n- Concurrently, low NAD+ limits PARP‑mediated DNA‑repair consumption, creating a feedback loop that prioritizes genome stability over growth [4].\n- Age‑related decline of NAMPT further lowers biosynthesis, amplifying the sink‑source imbalance [5].\n\n### Testable predictions\n\n1. Pharmacological or genetic inhibition of CD38 specifically in adipose‑tissue macrophages will increase NAD+ levels in that depot by at least 30 % after two weeks, measurable by LC‑MS/MS, without changing circulating SASP cytokines.\n2. The NAD+ rise will correlate with increased SIRT1‑dependent deacetylation of PGC‑1α (Western blot) and a 20 % rise in mitochondrial respiration (Seahorse assay) in isolated adipocytes.\n3. If senescent cells are left untouched, the metabolic improvements will not extend maximal lifespan in mice, indicating that NAD+ restoration alone is insufficient to overturn the upstream damage signal.\n4. Conversely, combining CD38 inhibition with intermittent senolytic treatment will produce additive gains in tissue NAD+ and improve frailty scores beyond either intervention alone.\n\n### Falsifiability\n\nIf CD38 blockade fails to raise tissue NAD+ or does not improve SIRT1 activity and mitochondrial function, the proposed sensor‑driven downgrade model would be refuted. Likewise, if NAD+ elevation without senescent‑cell removal consistently prolongs lifespan, the hypothesis that NAD+ loss is primarily a downstream compensatory response would need revision.